The estimated Net Worth of Kenneth T Jones is at least $115 Tisíc dollars as of 12 September 2023. Kenneth Jones owns over 2,505 units of Zynerba Pharmaceuticals Inc stock worth over $111,176 and over the last few years Kenneth sold ZYNE stock worth over $3,332.
Kenneth has made over 1 trades of the Zynerba Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Kenneth sold 2,505 units of ZYNE stock worth $3,332 on 12 September 2023.
The largest trade Kenneth's ever made was selling 2,505 units of Zynerba Pharmaceuticals Inc stock on 12 September 2023 worth over $3,332. On average, Kenneth trades about 1,253 units every 0 days since 2023. As of 12 September 2023 Kenneth still owns at least 85,520 units of Zynerba Pharmaceuticals Inc stock.
You can see the complete history of Kenneth Jones stock trades at the bottom of the page.
Kenneth's mailing address filed with the SEC is C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON, PA, 19333.
Over the last 9 years, insiders at Zynerba Pharmaceuticals Inc have traded over $154,101 worth of Zynerba Pharmaceuticals Inc stock and bought 224,703 units worth $2,383,877 . The most active insiders traders include John P. Butler, William J Federici a Michael Rapp. On average, Zynerba Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $12,515. The most recent stock trade was executed by Terri B Sebree on 12 September 2023, trading 12,401 units of ZYNE stock currently worth $16,493.
at zynerba pharmaceuticals (nasdaq: zyne), we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain through these therapeutics. our development pipeline includes patent-protected synthetic transdermal cannabinoid products, cbd gel – zyn002 and thc pro-drug patch – zyn001, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.
Zynerba Pharmaceuticals Inc executives and other stock owners filed with the SEC include: